{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-Cell+Non-Hodgkin+Lymphoma&page=34", "query": { "condition": "B-Cell Non-Hodgkin Lymphoma", "page": 34 }, "page_size": 10 }, "pagination": { "page": 34, "page_size": 10, "total_count": 2217, "total_pages": 222, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-Cell+Non-Hodgkin+Lymphoma&page=35&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-Cell+Non-Hodgkin+Lymphoma&page=33&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T11:00:35.402Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05565417", "title": "Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer", "Head and Neck Squamous Cell Carcinoma", "Triple Negative Breast Cancer", "Cutaneous Squamous Cell Carcinoma", "Hormone Receptor Positive Breast Carcinoma", "Small Bowel Cancer", "Esophageal Cancer", "Colorectal Cancer", "Diffuse Large B Cell Lymphoma", "Hodgkin Lymphoma", "Burkitt Lymphoma", "Follicular Lymphoma" ], "interventions": [ { "name": "IMT-009", "type": "DRUG" }, { "name": "Fruquintinib", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Immunitas Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2022-11-28", "completion_date": "2026-01", "has_results": false, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-10-16T11:00:35.402Z", "location_count": 9, "location_summary": "Tucson, Arizona • Denver, Colorado • Orlando, Florida + 6 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT05565417" }, { "nct_id": "NCT04260022", "title": "Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, Myeloid, Chronic", "Myeloid Leukemia", "Chronic Myeloid Leukemia", "Philadelphia Positive Acute Lymphoblastic Leukemia", "B Cell Precursor Type Acute Leukemia" ], "interventions": [ { "name": "Ascentage Pharma HQP1351 bioavailable inhibitor", "type": "DRUG" }, { "name": "Blinatumomab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ascentage Pharma Group Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 242, "start_date": "2020-01-09", "completion_date": "2030-03-31", "has_results": false, "last_update_posted_date": "2025-11-05", "last_synced_at": "2026-10-16T11:00:35.402Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Duarte, California • Atlanta, Georgia + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04260022" }, { "nct_id": "NCT00899951", "title": "Studying Fentanyl in Patients With Cancer", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Brain and Central Nervous System Tumors", "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Lymphoproliferative Disorder", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Pain", "Precancerous Condition", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "fentanyl citrate", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2007-10", "completion_date": "2009-07", "has_results": false, "last_update_posted_date": "2013-04-18", "last_synced_at": "2026-10-16T11:00:35.402Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00899951" }, { "nct_id": "NCT04537715", "title": "Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "All Malignancies", "Advanced Malignancies", "Hematologic Malignancy", "Solid Tumor", "Follicular Lymphoma (FL)", "Non-Hodgkin Lymphoma (NHL)", "Diffuse Large B-Cell Lymphoma (DLBCL)", "Epithelioid Sarcoma (ES)", "Synovial Sarcoma", "Renal Medullary Carcinoma", "Mesothelioma", "Rhabdoid Tumor" ], "interventions": [ { "name": "Tazemetostat", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" }, { "name": "Rifampin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Epizyme, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2020-04-23", "completion_date": "2023-04-03", "has_results": true, "last_update_posted_date": "2025-02-19", "last_synced_at": "2026-10-16T11:00:35.402Z", "location_count": 7, "location_summary": "Encinitas, California • Los Angeles, California • Chicago, Illinois + 4 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Canton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04537715" }, { "nct_id": "NCT00070018", "title": "S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "Yttrium-90 ibritumomab tiuxetan", "type": "BIOLOGICAL" }, { "name": "Indium-111 ibritumomab tiuxetan", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2004-02", "completion_date": "2015-01-08", "has_results": true, "last_update_posted_date": "2022-01-11", "last_synced_at": "2026-10-16T11:00:35.402Z", "location_count": 48, "location_summary": "Anchorage, Alaska • Burbank, California • Boise, Idaho + 33 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Burbank", "state": "California" }, { "city": "Boise", "state": "Idaho" }, { "city": "Decatur", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00070018" }, { "nct_id": "NCT02216890", "title": "Safety Study of SGN-CD70A in Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cell Carcinoma", "Mantle-Cell Lymphoma", "Diffuse, Large B-Cell, Lymphoma", "Follicular Lymphoma, Grade 3" ], "interventions": [ { "name": "SGN-CD70A", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2014-08", "completion_date": "2017-02-15", "has_results": false, "last_update_posted_date": "2018-04-19", "last_synced_at": "2026-10-16T11:00:35.402Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Duarte, California • Maywood, Illinois + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02216890" }, { "nct_id": "NCT01238146", "title": "Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Nodal Marginal Zone B-cell Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Splenic Marginal Zone Lymphoma" ], "interventions": [ { "name": "bendamustine hydrochloride", "type": "DRUG" }, { "name": "obatoclax mesylate", "type": "DRUG" }, { "name": "rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2010-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-06", "last_synced_at": "2026-10-16T11:00:35.402Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01238146" }, { "nct_id": "NCT03028103", "title": "Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Large B Cell Lymphoma", "Primary Mediastinal Lymphoma", "Mantle Cell Lymphoma", "Advanced Solid Tumor", "Marginal Zone Lymphoma" ], "interventions": [ { "name": "Tazemetostat", "type": "DRUG" }, { "name": "Fluconazole", "type": "DRUG" }, { "name": "Omeprazole", "type": "DRUG" }, { "name": "Repaglinide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Epizyme, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2017-03-27", "completion_date": "2019-11-29", "has_results": true, "last_update_posted_date": "2023-06-26", "last_synced_at": "2026-10-16T11:00:35.402Z", "location_count": 3, "location_summary": "Tucson, Arizona • Tampa, Florida • New York, New York", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tampa", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03028103" }, { "nct_id": "NCT05665062", "title": "Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "CLL/SLL", "NHL", "Mantle Cell Lymphoma", "Follicular Lymphoma", "Large B-cell Lymphoma", "Indolent B-Cell Non-Hodgkin Lymphoma", "Diffuse Large B Cell Lymphoma" ], "interventions": [ { "name": "SYNCAR-001", "type": "DRUG" }, { "name": "STK-009", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Synthekine", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2023-04-23", "completion_date": "2041-11", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-10-16T11:00:35.402Z", "location_count": 4, "location_summary": "Duarte, California • Buffalo, New York • New York, New York + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05665062" }, { "nct_id": "NCT02200380", "title": "A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "For Donors", "Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling", "For Recipients", "Acute Myelogenous Leukemia (AML)", "Acute Lymphoblastic Leukemia (ALL)", "Myelodysplastic Syndrome (MDS)", "Chronic Myelogenous Leukemia (CML)", "Non-Hodgkins Lymphoma (NHL)", "Hodgkins Disease (HD)", "Chronic Lymphocytic Leukemia (CLL)" ], "interventions": [ { "name": "CDX-301", "type": "DRUG" }, { "name": "CDX-301 and plerixafor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 36, "start_date": "2014-07", "completion_date": "2016-04-13", "has_results": false, "last_update_posted_date": "2017-04-07", "last_synced_at": "2026-10-16T11:00:35.402Z", "location_count": 8, "location_summary": "Los Angeles, California • Atlanta, Georgia • Indianapolis, Indiana + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02200380" } ] }